BioSpace News Archive

AMN Healthcare Services, Inc. (NYSE: AMN), healthcare’s leader and innovator in workforce solutions and staffing services, has scheduled a conference call to discuss its fourth quarter and full year 2019 financial results on Thursday, February 13, 2020 at 5:00 p.m. Eastern Time

Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico’s machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.

Perrigo Company plc Chief Executive Officer and President Murray S. Kessler will highlight the progress of the Company’s transformation into a consumer self-care company and discuss certain financial metrics for recently completed periods later at the 38th Annual J.P. Morgan Healthcare Conference.

Embody, Inc., a privately-held medical device company focused on soft tissue repair, announced today they have received a notice of award on a $2.5 million Phase II SBIR through the Defense Advanced Research Projects Agency (DARPA), extending the total funding from DARPA to $14.35 million in non-dilutive funding.

Digital Tomosynthesis uses a single sweep of X-ray exposures and streamlines operator workflow by separating the process of DT exposure acquisition from image volume formation.

50-week global study to enroll ~350 patients across broad ALS population

Alpha’s Offer Would Provide Opportunity for Stockholders to Receive a Cash Premium Through a $9.3 Million Tender Offer for 35% of Shares at $2.50 per Share

To be ISO 27001 compliant means Epiphany meets the security standards from the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC).

New additions to the Science 37 executive team will enhance both the patient and sponsor experiences as well as extend patient recruitment and trial execution efficiencies

Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid (CBD) therapeutics, announced today that it has further elucidated the mechanism of action (MOA) of its leading investigative drug candidate KLS-13019, a CBD-like molecule for the potential treatment of neuropathic pain.